QNTM
Get informed when a big investor buys or sells
+ FollowOvervalued by 99.8% based on the discounted cash flow analysis.
| Market cap | $17.19 Million |
|---|---|
| Enterprise Value | $13.71 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.11 |
| Beta | 0.4 |
| Outstanding Shares | 4,489,456 |
| P/E Ratio | -0.56 |
|---|---|
| PEG | -0.98 |
| Price to Sales | - |
| Price to Book Ratio | -3.83 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.71 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 1.46 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 7.74%▲ 3.83% |
|---|---|
| Total Invested | $1.23M▲ 31.01% |
| Investors Holding | 24▲ 1.00% |
No data
fsd pharma inc., through its subsidiary, fv pharma inc., produces medical cannabis in canada. the company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based...